Gilead submitted a new drug application for JAK1 inhibitor filgotinib to MHLW
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Gilead Sciences announced that thecompany(http://has submitted to The Ministry of Health, Labour and Welfare (MHLW) an application fornew drug(http://(NDA) of the oral selective JAK1 inhibitor filgotinib for the treatment of adult patients with rheumatoid arthritis (RA)Filgotinib's NDA and MAA are supported by data from the phase III FINCH ClinicalTrial(http://programFilgotinib is a highly selective JAK1 inhibitor that was discovered and developed by GalapagosGilead reached a $2 billion deal with Galapagos at the end of December 2015 to jointly develop filgotinibThe partnership will help strengthen Gilead's position in the field of inflammatory diseases, which will also be a new growth point for Gilead in the future, following the hepatitis C and HIV fieldsGilead and Galapagos are conducting a number of studies to assess the potential of filgotinib to treat a variety of inflammatory diseases, including phase III studies that treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
